Effective treatment of leukemia cutis with combination of rituximab, cladribine, and cyclophosphamide in patient with B-cell chronic lymphocytic leukemia.

摘要

B-cell chronic lymphocytic leukemia (B-CLL) is the most common adult leukemia in Western countries with annual incidence rate three to five cases per 100,000 [1]. Skin lesions in patients with CLL may represent nonspecific manifestations related to the impaired immune system or specific skin involvement, known as leukemia cutis (LC). The presence of LC varies from the type of leukemia but, in patients with B-CLL, is far less common comparing to T-cell leukemia [1,2]. The limited literature [2-8] shows that LC usually appears later in the course of the disease, after the symptoms of fatigue, night sweats, weight loss, easy bruising, heapatosplenomegaly, and enlarged lymph nodes. Solitary skin lesions manifesting as papules, plaques, nodules, tumors, more rarely as vesicobullous lesions, erythoderma, or paronychia may mimic other benign skin disorders [1, 8].